作为医药中间体,用于相关药物合成。
医药
合成路线 1(1. 合成:96929-05-4)
产率:100%
合成条件:With Bromotrichloromethane; 1,8-diazabicyclo[5.4.0]undec-7-ene In dichloromethane at -5 - 0℃; for 21 h;
实验步骤:将464g(1.61mmol)噻唑烷溶于2升二氯甲烷中,在-5至0℃下,与277克DBU混合。 然后在-5至0℃下,在1小时内滴加364g溴三氯甲烷,并将混合物在该温度下搅拌20小时。 加入1升水,并将反应混合物温热至室温。 将有机相用1升水和1升氯化铵水溶液洗涤,并在减压下在50℃下浓缩。 产量458g(100%),[产率校正纯度:96%] 1H-NMR(DMSO-d6):δ= 8.4(s,1H,SCHCOOEt),7.8(s,1H,NH),4.4(d,2H, CH2NH),4.3(q,2H,OCH2CH3,1.4(s,9H,叔丁基),1.3(t,3H,OCH2CH3)ppm。
参考文献:
- [1] Patent: US6639081, 2003, B1. Location in patent: Page/Page column 8
合成路线 2(2. 合成:96929-05-4)
产率:89.6%
合成条件:Stage #1: at 20 - 25℃; for 5 h; Stage #2: With sodium hydroxide In water; isopropyl alcohol
实验步骤:方法A:; 在20-25℃下,将24.6mmol溴丙酮酸乙酯加入到在47ml异丙醇中的5.0g(24.2mmol)硫代酰胺中,并将混合物搅拌5小时。 然后加入24.0mmol NaOH作为20%浓度的氢氧化钠水溶液,用甲基叔丁基醚萃取产物,用水和饱和氯化钠溶液洗涤有机相,用硫酸钠干燥,溶剂完全溶解。 剥去。 得到6.2g乙基噻唑羧酸盐,相当于89.6%的收率。 1H-NMR(DMSO-d6,ppm):8.41(s,1H,Ar-H),7.86(t,宽,NH),4.41(d,2H,CH2),4.30(q,2H, CH2),1.40(s,9H,叔丁基),1.30(t,3H,CH3)。
参考文献:
- [1] Tetrahedron, 1988, vol. 44, # 18, p. 5833 - 5844 [2] Synlett, 2008, # 15, p. 2379 - 2383 [3] Patent: US6642388, 2003, B1. Location in patent: Page/Page column 9 [4] Tetrahedron, 2018, vol. 74, # 5, p. 549 - 555 [5] Patent: CN103601742, 2016, B. Location in patent: Paragraph 0124-0126 [6] Patent: US6642388, 2003, B1. Location in patent: Page/Page column 9 [7] Tetrahedron, 1986, vol. 42, # 10, p. 2695 - 2702 [8] Journal of Organic Chemistry, 1985, vol. 50, # 15, p. 2787 - 2788 [9] Bioorganic and Medicinal Chemistry, 2003, vol. 11, # 16, p. 3475 - 3485 [10] Journal of the American Chemical Society, 2016, vol. 138, # 16, p. 5426 - 5432 [11] Patent: WO2017/132459, 2017, A1. Location in patent: Page/Page column 105-106 [12] Organic Process Research and Development, 2018, vol. 22, # 2, p. 190 - 199 [13] Journal of Asian Natural Products Research, 2010, vol. 12, # 11, p. 940 - 949 [14] Patent: WO2005/121130, 2005, A2. Location in patent: Page/Page column 392 [15] Bioorganic and Medicinal Chemistry Letters, 2012, vol. 22, # 15, p. 4994 - 4997 [16] Organic Letters, 2011, vol. 13, # 4, p. 680 - 683 [17] Journal of the American Chemical Society, 2002, vol. 124, # 38, p. 11272 - 11273 [18] Journal of Medicinal Chemistry, 2018, vol. 61, # 3, p. 834 - 864 [19] Bulletin of the Chemical Society of Japan, 1996, vol. 69, # 8, p. 2309 - 2316 [20] Patent: US6642388, 2003, B1. Location in patent: Page/Page column 8 [21] Patent: US6344562, 2002, B1. Location in patent: Page column 53 [22] ACS Medicinal Chemistry Letters, 2013, vol. 4, # 1, p. 132 - 136 [23] ACS Medicinal Chemistry Letters, 2017, vol. 8, # 4, p. 401 - 406